ClinicalTrials.gg
RecruitingNCT04715217Updated Dec 29, 2023

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

A Phase 1/2 interventional study of CD19-CD22 CAR-T cells in Lymphoma, B-Cell, sponsored by Shanxi Province Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 6 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-12-29.

Sponsored by Shanxi Province Cancer Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
6 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies testing cyclophosphamide in Lymphoma, B-Cell — 8 open to participants now, 12 under way, none of them phase 3. Cyclophosphamide · Lymphoma, B-Cell.

Planned enrollment
25th of 32
24 · median 37
Started
2021
with 4 others
Phase 1/2
7 of 32
3 open now
Primary completion
2024-10
later than 1 of 11 live
Registered
24th of 32
by date

Among the 32 studies testing cyclophosphamide in Lymphoma, B-Cell, this one is the 25th largest by planned enrollment, is one of 5 that started in 2021, is one of 7 in phase 1/2, reaches primary completion later than 1 of the 11 other live ones, and was the 24th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

8 of the 32 studies testing cyclophosphamide in Lymphoma, B-Cell are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 6 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing cyclophosphamide in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of B cell lymphoma.

Read the detailed description

A non randomized study ,plans to enrollment 24 subjects of B cell lymphoma .The subjects will divide into low, medium and high dose groups,to evaluate the safety and tolerability of CD19-CD22 CAR - T cells,to evaluate the preliminary efficacy and observe PK/PD parameters of CD19-CD22 CAR -T cells immunotherapy in patients with relapsed or refractory B cell lymphoma .

03

Conditions studied

  • Lymphoma, B-Cell

Browse trials for

04

Who can participate

Ages eligible
6 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 6-70 - year - old male or female subjects (including 6 years old and 70 years old, 6-18 subjects use only the recommended dose of treatment);
  2. The Clinical diagnosis of recurrent/ B cell lymphoma, after at least 2 courses of treatment, has not been achieved partial response, still in the continuous phase and progress, including the MRD positive, or recurrent intramedullary patients;
  3. Bone marrow samples inspection by using flow cytometry or organization pathology ,the cell membrane surface antigen CD19 and/or CD22 positive;
  4. Patients with lymphoma need to have a , measurable target lesions: lymph node x1.0 > 1.5 cm, outside the junction lesions > x1.0 1.0 cm;
  5. physical status score of 0 to 2 points;
  6. Expected lifetime is more than 12 weeks;
  7. The clinical laboratory test results of screening phase meet the following criteria: (7 days before the inspection without blood transfusion) ≥60 g/L (allowed to use recombinant human erythropoietin); ≥ 50 x 10 \^ 9 / L ; ALC≥0.3×10\^9/L; ≥0.75×10\^9/L (allowed to use granulocyte colony stimulating factor); ≤3ULN,ALT≤3ULN,≤2ULN;Ccr≥30 mL/min/1.73 m2;
  8. Cardiopulmonary function: > 40%; Baseline blood oxygen saturation > 95%;
  9. Has a history of /allogeneic hematopoietic stem cell transplantation patients: transplantation in 3 months ago, no grade 2 or more active (GVHD), more than a month without immune inhibitors.

Exclusion criteria

Exclusion Criteria:

  1. The active , HBV - DNA detection lower limit of the subjects above research center; virus (HCV) antibody positive and peripheral blood HCV - RNA positive subjects; Antibodies to positive subjects; Early syphilis screening antibody positive;
  2. The other clinical significance of active virus, bacterial infection, or failing to control systemic fungal infection;
  3. Any instability of systemic disease, including but not limited to, unstable angina, cerebrovascular accident, or transient ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), (NYHA) classification level III or higher congestive heart failure, drug control of serious arrhythmia, liver, kidney or metabolic diseases, as well as the standard treatment cannot control high blood pressure;
  4. In past two years, because of diseases such as crohn's disease, rheumatoid arthritis and systemic lupus erythematosus (sle), etc.) causing end-organ damage, or need systemic application of drugs;
  5. Had a history of the central nervous system diseases, such as epilepsy, serious brain damage, dementia, Parkinson's disease, psychosis,etc which influence the appraising of test,;
  6. Diagnosed with other active in past five years(the basal or scaly skin cancer, superficial bladder cancer, breast cancer in situ, which has been cured and does not require follow-up treatment are not included );
  7. Known allergic to cyclophosphamide, fluorine dara marina or CAR - T cell s including accessories, DMSO ;
  8. Patients with pregnancy or lactation, patients do not want to take effective measures within 6months after infusion CAR-T cells;
  9. The other situations that researchers determined doesn't fit to participate in this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Low Dose Group

    CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10\^6 CAR+T cells/kg.

    Biological: CD19-CD22 CAR-T cells

  • Experimental
    Middle Dose Group

    CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of middle dose group will be intravenously infuse with 2.0×10\^6 CAR+Tcells/kg.

    Biological: CD19-CD22 CAR-T cells

  • Experimental
    High Dose Group

    CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of high dose group will be intravenously infuse with 5.0×10\^6 CAR+Tcells/kg.

    Biological: CD19-CD22 CAR-T cells

  • Experimental
    Amplification Dose Group

    CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10\^6 CAR+Tcells/kg.

    Biological: CD19-CD22 CAR-T cells

Interventions

  • BiologicalCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A autologous doping CAR - T cells injection targets with CD19 and CD22,fluorine dara marina injection(30 mg/m2,QD×3d) and cyclophosphamide injection (300 mg/m2,QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .

    Also known as: Fluorine dara marina injection, Cyclophosphamide injection

06

What researchers measure

Primary outcomes

  1. DLT

    Observe wether dose limiting toxicity will happened in dose escalation phase

    Time frame: Form infusion CAR-T cells to 28 days after infusion

  2. ORR

    The overall response rate after CD19-CD22 CAR-T Cells immunotherapy

    Time frame: Form infusion CAR-T cells to 2 years after infusion

Secondary outcomes

  1. Incidence of various types of adverse recation

    According to CTCAE 5.0, record the level , type of adverse events, evaluat the correlation of CD19-CD22 CAR-T cells

    Time frame: Form infusion CAR-T cells to 2 years after infusion

  2. PFS

    Progression-free surial

    Time frame: Form infusion CAR-T cells to 2 years after infusion

  3. DOR

    Duration of Response

    Time frame: Form infusion CAR-T cells to 2 years after infusion

  4. OS

    Overall survival

    Time frame: Form infusion CAR-T cells to subjects died,assessed up to 60 months

  5. Cmax

    By measuring the CAR - T cells copy number and the positive rate, peak plasma concentration is determined

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

  6. Tmax

    The maximum concentration of time

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

  7. AUC(0-720d)

    Area under the plasma concentration versus time curve

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

  8. Concentration of IL2 level

    The levels of cytokines(IL2 )in peripheral blood

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

  9. Concentration of IL6 level

    The levels of cytokines(IL6 )in peripheral blood

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

  10. Concentration of IL10 level

    The levels of cytokines( IL10 )in peripheral blood

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

  11. Concentration of TNF-α level

    The levels of cytokines(TNF-α)in peripheral blood

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

  12. Concentration of IFN-γ level

    The levels of cytokines(IFN-γ )in peripheral blood

    Time frame: Before removal of lymphocytes, before CAR - T cells infusion, Day1, Day3, Day5, Day7, Day10, Day14, Day21, Day28, Month2, Month3, Month6, Month9, Month12, Month15, Month18, Month21, Month24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Plan to Share Clinical Study Report within six months after the study completed

Time frame: Within six months after the study completed

Access criteria: Research site

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Oct 2024, 45 months after the start.

Of 52 non-industry phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 82. This study's planned 45 months is below that.

Counting every sponsor, half of 94 studies reached it within 71 months; a quarter within 55 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 20, 2021
StartActual
Jan 4, 2021
Primary completionEst.
Oct 31, 2024
CompletionEst.
Oct 31, 2025
Last update
Dec 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04715217
Lead sponsor
Shanxi Province Cancer Hospital
Collaborators
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Responsible party
Sponsor
First posted
Jan 20, 2021
Start date
Jan 4, 2021
Primary completion
Oct 31, 2024 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Dec 29, 2023

Study contacts

Liping Su, M.D.
Contact
sulp2005@sohu.com
+8613835158122
Liping Su, M.D.
principal investigator · Hematology Department of ShanXi Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion